Drugplain

memantine hydrochloride and donepezil hydrochloride 10 mg/1

memantine hydrochloride and donepezil hydrochloride · CAPSULE, EXTENDED RELEASE · Vitruvias Therapeutics, Inc.

No Recall HistoryCurrently in Shortage
Plain English

This medication is a combination of two drugs used to treat moderate to severe Alzheimer's disease by helping to improve memory and thinking ability. It comes as an extended-release capsule taken by mouth.

Key Facts

Brand Name
memantine hydrochloride and donepezil hydrochloride
Generic Name
memantine hydrochloride and donepezil hydrochloride
NDC Code (Product)
69680-185
Manufacturer
Vitruvias Therapeutics, Inc.
Strength
10 mg/1
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Marketing Status
Application #
ANDA216901
Marketing Start
07/16/2025

Recall History

No Recall History

Side Effects Reported to FDA

FDA FAERS database · These are reported events, not confirmed side effects

abnormal behaviour1 reports
agitation1 reports
death1 reports
irritability1 reports
restlessness1 reports

Full Prescribing Information

Source: FDA Drug Label (SPL)For healthcare professionals

Indications & Usage

1 INDICATIONS AND USAGE Memantine and donepezil hydrochlorides extended-release capsules is indicated for the treatment of moderate to severe dementia of the Alzheimer's type in patients stabilized on 10 mg of donepezil hydrochloride once daily. Memantine and donepezil hydrochlorides extended-release capsules is a combination of memantine hydrochloride, an NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor, indicated for the treatment of moderate to severe dementia of the Alzheimer's type in patients stabilized on 10 mg of donepezil hydrochloride once daily. ( 1 )

Dosage & Administration

2 DOSAGE AND ADMINISTRATION For patients on donepezil hydrochloride 10 mg only, the recommended starting dose of memantine and donepezil hydrochlorides extended-release capsules is 7 mg/10 mg, taken once daily in the evening. The dose should be increased in 7 mg increments to the recommended maintenance dose of 28 mg/10 mg. The minimum recommended interval between dose increases is one week. ( 2.1 ) Patients on memantine hydrochloride (10 mg twice daily or 28 mg extended-release once daily) and donepezil hydrochloride 10 mg once daily can be switched to memantine and donepezil hydrochlorides extended-release capsules 28 mg/10 mg, taken once daily in the evening. ( 2.1 ) Memantine and donepezil hydrochlorides extended-release capsules can be taken with or without food, whole or sprinkled on applesauce; do not divide, chew, or crush. ( 2.2 ) Severe renal impairment: the recommended maintenance dose for memantine and donepezil hydrochlorides extended-release capsules is 14 mg/10 mg once daily in the evening. ( 2.3 ) 2.1 Recommended Dosing The recommended dose of memantine and donepezil hydrochlorides extended-release capsules is 28 mg/10 mg once daily. For patients stabilized on donep

Contraindications

4 CONTRAINDICATIONS Memantine and donepezil hydrochlorides extended-release capsules is contraindicated in patients with known hypersensitivity to memantine hydrochloride, donepezil hydrochloride, piperidine derivatives, or to any excipients used in the formulation. Memantine and donepezil hydrochlorides extended-release capsules is contraindicated in patients with known hypersensitivity to memantine hydrochloride, donepezil hydrochloride, piperidine derivatives, or to any excipients used in the formulation. ( 4 )

Drug Interactions

7 DRUG INTERACTIONS Combined use with NMDA antagonists: use with caution. ( 7.2 ) Memantine and donepezil hydrochlorides extended-release capsules may interfere with anticholinergic medications. ( 7.4 ) Concomitant administration of succinylcholine, similar neuromuscular blocking agents, or cholinergic agonists may lead to synergistic effect. ( 7.5 ) 7.1 Use of Memantine with Drugs That Make the Urine Alkaline The clearance of memantine was reduced by about 80% under alkaline urine conditions at pH 8. Therefore, alterations of urine pH towards the alkaline condition may lead to an accumulation of the drug with a possible increase in adverse reactions. Urine pH is altered by diet, drugs (e.g., carbonic anhydrase inhibitors, sodium bicarbonate) and clinical state of the patient (e.g., renal tubular acidosis or severe infections of the urinary tract). Hence, memantine should be used with caution under these conditions. 7.2 Use of Memantine with Other N-methyl-D-aspartate (NMDA) Antagonists The combined use of memantine hydrochloride with other NMDA antagonists (amantadine, ketamine, and dextromethorphan) has not been systematically evaluated and such use should be approached with caut

Adverse Reactions

6 ADVERSE REACTIONS The following serious adverse reactions are discussed below and elsewhere in the labeling. Cardiovascular Conditions [see Warnings and Precautions ( 5.2 )] Peptic Ulcer Disease and Gastrointestinal Bleeding [see Warnings and Precautions ( 5.3 )] Nausea and Vomiting [see Warnings and Precautions ( 5.4 )] Genitourinary Conditions [see Warnings and Precautions ( 5.5 )] Seizures [see Warnings and Precautions ( 5.6 )] Pulmonary Conditions [see Warnings and Precautions ( 5.7 )] The most common adverse reactions, occurring at a frequency of at least 5% and greater than placebo with memantine hydrochloride extended-release 28 mg/day, were headache, diarrhea, and dizziness. ( 6.1 ) The most common adverse reactions, occurring at a frequency of at least 5% in patients receiving donepezil hydrochloride and at twice or more the placebo rate, include diarrhea, anorexia, vomiting, nausea, and ecchymosis. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Xiamen LP Pharmaceutical Co., Ltd. at 1-877-676-0778 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction

Frequently Asked Questions

What is memantine hydrochloride and donepezil hydrochloride used for?

This medication is a combination of two drugs used to treat moderate to severe Alzheimer's disease by helping to improve memory and thinking ability. It comes as an extended-release capsule taken by mouth.

Is memantine hydrochloride and donepezil hydrochloride a controlled substance?

memantine hydrochloride and donepezil hydrochloride is not classified as a controlled substance by the DEA.

What is the generic name for memantine hydrochloride and donepezil hydrochloride?

The generic name for memantine hydrochloride and donepezil hydrochloride is memantine hydrochloride and donepezil hydrochloride. There are 4 other brand versions of memantine hydrochloride and donepezil hydrochloride.

What is the NDC code for memantine hydrochloride and donepezil hydrochloride 10 mg/1?

The NDC (National Drug Code) for memantine hydrochloride and donepezil hydrochloride 10 mg/1 is 69680-185, listed by Vitruvias Therapeutics, Inc..

Product NDC

69680-185

Package NDC

69680-185-30

Other memantine hydrochloride and donepezil hydrochloride Dosages

Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.

Data from openFDA · Public domain (CC0 1.0)